ArticleJournal of experimental & clinical cancer research : CR2010
Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer.
Article in Journal of experimental & clinical cancer research : CR, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Design and experimental validation of OPERA_MET-A panel for deep methylation analysis by next generation sequencing.Frontiers in oncology · 2022Article
- Potential Prognostic Role ofCells · 2020Article
- Osteonectin as a screening marker for pancreatic cancer: A prospective study.The Journal of international medical research · 2018Article
- Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options.World journal of gastroenterology · 2017Review
- Drug metabolism and pancreatic cancer.Annals of gastroenterology · 2017Review
- A holistic approach to dissecting SPARC family protein complexity reveals FSTL-1 as an inhibitor of pancreatic cancer cell growth.Scientific reports · 2016Article
- Review
- Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.Cancer letters · 2015Review
- SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.World journal of gastroenterology · 2014Review
- Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects.World journal of gastroenterology · 2014Review
- Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma.Cancer research · 2014Article
- Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression.Journal of experimental & clinical cancer research : CR · 2013Article
- Loss of SPARC in bladder cancer enhances carcinogenesis and progression.The Journal of clinical investigation · 2013Article
- Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?Haematologica · 2013Review
- Aberrant methylation of SPARC in human hepatocellular carcinoma and its clinical implication.World journal of gastroenterology · 2012Article
- Alteration in methylation pattern of oncogene Akt1 promoter region in bladder cancer.Molecular biology reports · 2012Article
- Methylation of the APAF-1 and DAPK-1 promoter region correlates with progression of renal cell carcinoma in North Indian population.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Article
- Molecular targeted approaches for treatment of pancreatic cancer.Current pharmaceutical design · 2011Review
- Article
- Genetic factors affecting patient responses to pancreatic cancer treatment.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe secreted protein acidic and rich in cysteine (SPARC) plays a pivotal role in regulating cell-matrix interactions and tumor angiogenesis, proliferation, and migration. Detection of SPARC gene methylation may be useful as a tumorigenesis marker for early detection of pancreatic cancer.
methodsMethylation of the SPARC gene transcriptional regulation region (TRR) was detected using bisulfite-specific (BSP) PCR-based sequencing analysis in 40 cases of pancreatic cancer and the adjacent normal tissues, 6 chronic pancreatitis tissues, and 6 normal pancreatic tissues. BSP cloning-based sequencing analysis was also performed in selected cases. Clinicopathological data from the cancer patients were collected and analyzed.
resultsAnalysis of SPARC gene TRR methylation showed two hypermethylation wave peak regions: CpG Region 1 (CpG site 1-7) and CpG Region 2 (CpG site 8-12). Pancreatic tissues have shown methylation in both regions with gradual increases from normal, chronic pancreatitis, and adjacent normal tissues to cancerous tissues. However, Methylation of CpG Region 2 was more sensitive than CpG Region 1 in pancreatic tumorigenesis. Furthermore, the methylation level of CpG Region 2 was associated with increased tumor size and exposure to the risk factors (tobacco smoke and alcohol consumption) for developing pancreatic cancer.
conclusionMethylation of the SPARC gene, specifically CpG Region 2, may be an early event during pancreatic tumorigenesis and should be further evaluated as a tumorigenesis marker for early detection of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.